This Market-Beating Stock Just Gave Investors More Reasons to Invest
Regeneron recently earned a key regulatory approval. The company also expanded its pipeline with an acquisition.
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023
TARRYTOWN, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2023 financial and operating results on Thur...
This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost
Regeneron's sales growth rate has been struggling over the past year. Revenue from its top-selling drug, Eylea, fell 7% in the most recent quarter.
Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare
Regeneron Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Tarrytown that has played a key role in the fight against COVID-19. Regeneron's revenue for the second quarter of 2023 w...
Regeneron's pricing deal with federal government may have ‘far-reaching consequences,' analysts say
Regeneron Pharmaceuticals Inc.'s REGN, +0.74% agreement with the federal government to limit the list price of any new COVID monoclonal antibody commercialized as a result of their public-private p...
Is Regeneron Stock Fully Valued At $820?
Regeneron stock (NASDAQ: REGN) has seen a 6% rise in a month, compared to a 1% fall for the broader S&P500 index.
Regeneron CFO Landry to retire, top accountant Fenimore to become CFO
Regeneron Pharmaceuticals Inc. REGN, +0.66% said late Friday that Chief Financial Officer Robert E. Landry will retire in February, and Christopher Fenimore, the pharma company's current head of ac...
2 Top Biotech Stocks to Buy in September
Vertex and Regeneron have delivered solid financial results and stock market performance. Both biotechs have exciting pipelines that should produce key new approvals or label expansions.
Regeneron (REGN) Gains 13% in 1 Month on FDA Nod For Eylea HD
Regeneron (REGN) gains 13% in a month on the FDA's approval of a higher dose of Eylea and other positive updates.
Is Regeneron Stock a Buy Now?
Regeneron's latest regulatory approval comes at an opportune time. The company's current lineup should continue generating growing sales.
Regeneron gets federal funding for next-generation COVID treatment
Regeneron Pharmaceuticals Inc. REGN, -0.32% said Tuesday that the Biomedical Advanced Research and Development Authority has agreed to support the development, manufacturing and licensure of a next...
Regeneron (REGN) Gets FDA Nod for Higher Dose of Eylea
Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz.
Cramer dubs Regeneron stock a ‘favourite' after two new FDA approvals
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) secured FDA approval for Eylea HD – a higher-dose of its treatment for Macular Degeneration on Monday. Jim Cramer is bullish on Regeneron stock Shares o...
This biotech name is one of Jim Cramer's favorite stocks and he thinks it can go even higher
"I think it's going to be worth more," Jim Cramer said Monday after Regeneron got good news from the FDA on its macular degeneration treatment.
Cramer's Stop Trading: Regeneron
CNBC's Jim Cramer explains why he is keeping an eye on shares of Regeneron
Related Companies